Get startedLog in
    Picture of ORYZON Genomics SA logo

    ORY — ORYZON Genomics SA News Story

    0.000.00%
    es flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapSucker Stock
    All News

    Brief: Oryzon Says First Patient Dosed In Phase I/II Clinical Trial Of Iadademstat with Immune Checkpoint Inhibitors

    Picture of ORYZON Genomics SA logoORYZON Genomics SA
    15/04/2025 07:28
    April 15 (Reuters) - Oryzon Genomics SA ORY.MC:

ANNOUNCES FIRST PATIENT DOSED IN NCI-SPONSORED PHASE I/II CLINICAL TRIAL OF IADADEMSTAT

IADADEMSTAT TESTED IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS (ICI) IN FIRST LINE SMALL CELL LUNG CANCER (SCLC) PATIENTS WITH EXTENSIVE DISEASE

Source text: https://tinyurl.com/4wem4ah3

Further company coverage: ORY.MC

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

    Recent news on ORYZON Genomics SA

    See all news